市場調査レポート

商品コード

1767679

ハーセプチン市場：種類別、用途別、流通チャネル別、支払者の種類別、投与経路別、治療ライン別、患者属性別、地域別

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

出版日: 2025年06月12日
発行: Coherent Market Insights
ページ情報: 英文 145 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,500 663,660円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,032,360円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,474,800円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.48円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ハーセプチン市場は2025年に33億米ドルと推定され、2032年には48億4,000万米ドルに達すると予測され、2025年から2032年までのCAGRは5.62%で推移すると予測されます。

分析範囲		分析詳細
基準年	2024年	市場規模 (2025年)	33億米ドル
実績データ	2020～2024年	予測期間	2025～2032年
予測期間のCAGR (2025～2032年)	5.62%	予測金額 (2032年)	48億4,000万米ドル

世界のハーセプチン市場は、HER2陽性乳がんの有病率の増加と標的治療に対する需要の高まりに牽引され、近年著しい成長を遂げています。トラスツズマブとしても知られるハーセプチンは、乳がんの約20～30％で過剰発現するHER2タンパク質を特異的に標的とするモノクローナル抗体です。

この薬剤はHER2陽性乳がんの治療状況に革命をもたらし、患者の予後と生存率を改善しました。市場の成長は、HER2陽性転移性胃がんの治療への使用を含む、ハーセプチンの適応拡大によってさらに促進されています。さらに、バイオシミラーの開発や他の治療法との併用によるハーセプチンの採用拡大が、市場成長の新たな道を開いています。当レポートでは、世界のハーセプチン市場を詳細に分析し、市場促進要因、市場抑制要因、機会、将来展望などを明らかにします。

市場力学：

世界のハーセプチン市場は、HER2陽性乳がんの罹患率の上昇、標的治療に対する意識の高まり、個別化医療に対する需要の高まりなど、いくつかの要因によって牽引されています。また、HER2発現のコンパニオン診断検査の開発も、ハーセプチン治療が最も有効であると考えられる患者の特定を可能にし、市場の成長に寄与しています。しかし、ハーセプチン治療は高額であるため、地域によってはその利用が制限される可能性があり、市場成長は抑制されています。さらに、バイオシミラーの出現や一部の国におけるハーセプチンの特許切れも、先発品の市場シェアに影響を与える可能性があります。これらの課題にもかかわらず、ハーセプチンの他のHER2陽性がんへの適応拡大、新規薬剤の併用開発、新興経済諸国におけるハーセプチンの採用拡大など、市場には大きな成長機会があります。さらに、ハーセプチンの有効性と安全性の向上を目指した研究開発が進められており、今後の市場成長の原動力となることが期待されます。

当レポートの主な特徴

当レポートは、世界のハーセプチン市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模・CAGRを掲載しています。
また、各セグメントの潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
また、市場の促進要因・抑制要因や機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
世界のハーセプチン市場における主要企業プロファイルを、企業概要、製品ポートフォリオ、主要なハイライト、財務実績、戦略などの以下のパラメータに基づいて掲載しています。
当レポートの洞察を用いて、マーケティング担当者や企業の経営陣が、将来の製品発売・提携・市場拡大・マーケティング戦術に関する、十分な情報に基づいた意思決定を下すことができます。
「世界のハーセプチン市場」レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
利害関係者は、世界のハーセプチン市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 3.30 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.62%	2032 Value Projection:	USD 4.84 Bn

The global Herceptin market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.

The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the global Herceptin market, highlighting its key drivers, restraints, opportunities, and future prospects.

Market Dynamics:

The global Herceptin market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global Herceptin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Herceptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Herceptin market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Biologic
- Biosimilars
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer Treatment
- Gastric Cancer Treatment
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Payer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
Administration Route Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
Treatment Line Insights (Revenue, USD Bn, 2020 - 2032)
- First-line Treatment
- Second-line Treatment
- Third-line Treatment
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Pediatric
- Adult
- Geriatric
- Gender
- Male
- Female
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Genentech (Roche)
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK (GlaxoSmithKline)
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Herceptin Market, By Type
- Global Herceptin Market, By Application
- Global Herceptin Market, By Distribution Channel
- Global Herceptin Market, By Payer Type
- Global Herceptin Market, By Administration Route
- Global Herceptin Market, By Treatment Line
- Global Herceptin Market, By Patient Demographics
- Global Herceptin Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Breast Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gastric Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
First-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Second-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Third-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Pediatric
  - Adult
  - Geriatric
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Male
  - Female

11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

Genentech (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
EMD Serono
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

13. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

14. References and Research Methodology

References
Research Methodology
About us

ハーセプチン市場：種類別、用途別、流通チャネル別、支払者の種類別、投与経路別、治療ライン別、患者属性別、地域別

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

市場力学：

当レポートの主な特徴

目次

第1章分析目的と前提条件

第2章市場の展望

第3章市場力学・規制・動向分析

第4章世界のハーセプチン市場：種類別（2020～2032年）

第5章世界のハーセプチン市場：用途別（2020～2032年）

第6章世界のハーセプチン市場：流通チャネル別（2020～2032年）

第7章世界のハーセプチン市場：支払者の種類別（2020～2032年）

第8章世界のハーセプチン市場：投与経路別（2020～2032年）

第9章世界のハーセプチン市場：治療ライン別（2020～2032年）

第10章世界のハーセプチン市場：患者属性別（2020～2032年）

第11章世界のハーセプチン市場：地域別（2020～2032年）

第12章競合情勢

第13章アナリストの提言

第14章参考文献と調査手法

Market Dynamics:

Key Features of the Study:

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)

5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)

6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)

7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)

8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)

9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)

10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)

11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)

12. Competitive Landscape

13. Analyst Recommendations

14. References and Research Methodology

ハーセプチン市場：種類別、用途別、流通チャネル別、支払者の種類別、投与経路別、治療ライン別、患者属性別、地域別

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

市場力学：

当レポートの主な特徴

目次

第1章 分析目的と前提条件

第2章 市場の展望

第3章 市場力学・規制・動向分析

第4章 世界のハーセプチン市場：種類別（2020～2032年）

第5章 世界のハーセプチン市場：用途別（2020～2032年）

第6章 世界のハーセプチン市場：流通チャネル別（2020～2032年）

第7章 世界のハーセプチン市場：支払者の種類別（2020～2032年）

第8章 世界のハーセプチン市場：投与経路別（2020～2032年）

第9章 世界のハーセプチン市場：治療ライン別（2020～2032年）

第10章 世界のハーセプチン市場：患者属性別（2020～2032年）

第11章 世界のハーセプチン市場：地域別（2020～2032年）

第12章 競合情勢

第13章 アナリストの提言

第14章 参考文献と調査手法

Market Dynamics:

Key Features of the Study:

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)

5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)

6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)

7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)

8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)

9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)

10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)

11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)

12. Competitive Landscape

13. Analyst Recommendations

14. References and Research Methodology

第1章分析目的と前提条件

第2章市場の展望

第3章市場力学・規制・動向分析

第4章世界のハーセプチン市場：種類別（2020～2032年）

第5章世界のハーセプチン市場：用途別（2020～2032年）

第6章世界のハーセプチン市場：流通チャネル別（2020～2032年）

第7章世界のハーセプチン市場：支払者の種類別（2020～2032年）

第8章世界のハーセプチン市場：投与経路別（2020～2032年）

第9章世界のハーセプチン市場：治療ライン別（2020～2032年）

第10章世界のハーセプチン市場：患者属性別（2020～2032年）

第11章世界のハーセプチン市場：地域別（2020～2032年）

第12章競合情勢

第13章アナリストの提言

第14章参考文献と調査手法